Moderna, Inc. (MRNA)
| Market Cap | 21.98B +110.1% |
| Revenue (ttm) | 2.23B -30.0% |
| Net Income | -3.19B |
| EPS | -8.16 |
| Shares Out | 396.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,050,524 |
| Open | 52.24 |
| Previous Close | 52.13 |
| Day's Range | 51.66 - 57.79 |
| 52-Week Range | 22.28 - 59.55 |
| Beta | 1.03 |
| Analysts | Hold |
| Price Target | 43.30 (-21.84%) |
| Earnings Date | Jul 31, 2026 |
About MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price target is $43.3, which is a decrease of -21.84% from the latest price.
News
BofA says VRBPAC docs look supportive but keeps Moderna at Underperform
BofA reviewed the VRBPAC briefing docs released this morning. Overall, the tone of the documents and proposed points of focus should foster some debate but look supportive for approval, the…
FDA posts briefing docs for meeting to discuss Moderna influenza vaccine
On June 18, the FDA is convening a meeting of the Vaccines and Related Biological Products Advisory Committee to discuss the benefit-risk assessment of mFlusiva, an mRNA-based trivalent influenza vacc...
Moderna flu vaccine briefing docs ‘read favorably,’ says Jefferies
Ahead of the FDA hosting an advisory committee meeting on Moderna’s (MRNA) mFLUSIVA mRNA vaccine for seasonal flu on Thursday, Jefferies says the firm finds the FDA’s tone and analyses…
US FDA staff says data may support effectiveness of Moderna's flu vaccine in older adults
The U.S. Food and Drug Administration's staff reviewers said preliminary assessment of Moderna's flu shot data may support effectiveness in adults 65 years and older.
Moderna announces executive changes ahead of potential launches
Moderna appointed a new chief commercial officer and widened its president's role to oversee certain franchises, the vaccine maker said on Tuesday, as it prepares for potential product launches over...
Moderna president Stephen Hoge to assume expanded role, Ester Banque named CCO
Moderna (MRNA) announced changes to its operating model to support its short- and long-term business goals. As Moderna executes its long-range plan to become a diversified, multi-modality biotechnolog...
Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028
Dr. Stephen Hoge, President of Moderna, to Assume an Expanded Role With Operational Oversight of the Company's Infectious Disease, Intismeran and Rare Disease Franchises Ester Banque to Join Moderna a...
Moderna Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management outlined a strategy focused on global expansion, product diversification, and disciplined cost control, targeting up to 10% revenue growth and cash flow breakeven by 2028. Key pipeline assets, including intismeran and a norovirus vaccine, are expected to drive substantial future growth, with new launches and market share gains in both the U.S. and Europe.
Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%[1] The INTERCEPT-Lynch trial is part of a scientific collaboration between the Universi...
Moderna price target raised to $34 from $32 at BofA
BofA raised the firm’s price target on Moderna (MRNA) to $34 from $32 and keeps an Underperform rating on the shares after having hosted Moderna’s CEO for a group lunch.
Moderna Launches Moderna Direct with “eCommerce Powered by FFF Enterprises™”
eCommerce Powered by FFF Enterprises™ delivers an enhanced ordering experience for Moderna customers. eCommerce Powered by FFF Enterprises™ delivers an enhanced ordering experience for Moderna custome...
Moderna to Present at Upcoming Conference in June 2026
CAMBRIDGE, MA / ACCESS Newswire / June 2, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Goldman Sachs 47th Annual Global Healthca...
Moderna Transcript: Study update
Intismeran, an individualized mRNA neoantigen therapy, showed a 49% reduction in recurrence risk and strong safety in phase II melanoma trials. Mechanistic data confirmed robust, durable T cell responses linked to efficacy, supporting expansion to other cancers and large-scale manufacturing.
Moderna Press release: Study update
Moderna issued a press release on June 1, 2026, disclosing material business information to investors.
Moderna Slides: Study update
Moderna has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Moderna, Merck to present 5-year data for intismeran autogene
Moderna (MRNA) and Merck (MRK), known as MSD outside of the United States and Canada, announced detailed results from a planned five-year follow-up analysis of the Phase 2b randomized KEYNOTE-942/mRNA...
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurr...
Moderna partners with global health coalition to develop Bundibugyo Ebola vaccine
Moderna said on Monday it has partnered with the Coalition for Epidemic Preparedness Innovations to develop a potential vaccine against Bundibugyo ebolavirus, the strain linked to the ongoing Ebola...
Moderna expands pact with CEPI to advance potential vaccine against BDBV
Moderna (MRNA) announced an expanded collaboration with the Coalition for Epidemic Preparedness Innovations, or CEPI, to advance the development of a potential vaccine against Bundibugyo ebolavirus, o...
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
Coalition for Epidemic Preparedness Innovations funding builds on Moderna's prior filovirus research and supports preclinical development and Phase 1 clinical evaluation CAMBRIDGE, MA / ACCESS Newswir...
Moderna Transcript: Bernstein 42nd Annual Strategic Decisions Conference
The business has evolved from research to a global commercial platform, with a diversified vaccine and oncology pipeline, robust cost management, and deep integration of AI across operations. AI and quantum computing are expected to accelerate drug discovery and operational efficiency, while new competitors validate the vaccine market.
Moderna, Merck cancer combo cuts melanoma spread risk at five years
Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body by 59% after five years of follow-up, data from a mid-stage trial showed Th...
US FDA to hold expert committee meeting to review Moderna's flu vaccine
The U.S. FDA said on Thursday it would hold a meeting of outside experts next month to review Moderna's experimental flu shot.
FDA to hold advisory hearing to debate Moderna’s flu vaccine, Bloomberg reports
Moderna’s (MRNA) experimental mRNA-based flu vaccine will be reviewed by an FDA advisory panel on June 18 ahead of an August 5 approval decision, signaling a possible return to greater…